Screener
4D Molecular Therapeutics FDMT Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$72.94M-33.4% | -$68.76M-43.3% | —— | -$56.88M-29.7% | -$54.66M-56.4% | ||
| $1.28M+9.8% | $1.27M+20.7% | $1.22M+10.9% | $1.26M+6.0% | $1.17M-2.3% | ||
| $5.88M+18.7% | $4.45M-36.3% | $5.55M-26.7% | $4.52M-30.4% | $4.96M-18.4% | ||
| -$70M-61.4% | -$68.13M-42.6% | —— | -$46.5M-58.2% | -$43.38M-43.4% | ||
| $55K-90.1% | $0-100% | —— | —— | $557K+59.6% | ||
| $25.54M+284% | $68.89M+116% | -$128.85M— | $17.78M— | -$13.85M+81.2% | ||
| $42.34M+4,812% | $11.48M— | $111.98M+18,533% | $116K-79.6% | $862K-95.0% | ||
| —— | $12.25M+177% | —— | -$28.6M-1,779% | -$56.37M+34.9% | ||
| -$70.05M-59.5% | -$68.13M-42.2% | —— | -$46.41M-48.9% | -$43.93M-43.6% |
FAQ
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
